<DOC>
	<DOCNO>NCT02048969</DOCNO>
	<brief_summary>The purpose study test feasibility measure flumazenil-induced change cortical GABA level observe localized 1H-MRS relation change severity hepatic encephalopathy ( HE ) subject non-alcoholic liver cirrhosis . This study double-blind , placebo-controlled , randomize , cross-over design .</brief_summary>
	<brief_title>Treatment Hepatic Encephalopathy With Flumazenil Change Cortical GABA Levels MRS</brief_title>
	<detailed_description>Subjects refer PI Yale Liver Center . If interested participating , contact research assistant initial phone screening . If subject pass screen , appointment make MRS fMRI Yale Magnetic Resonance Research Center ( MRRC ) . Subjects ask abstain HE medication ( e.g . lactulose and/or rifaximin ) 12 hour prior appointment . At appointment MRS/fMRI , receive two IVs , one medication infusion another periodic blood draw MRS . Subjects blindly randomize one two group : A B . Group A receive flumazenil ( Romazicon ) Group B receive placebo ( saline ) . One week post-infusion , patient crossover group ; originally Group A crossover Group B originally Group B crossover Group A . Once ready , prim dose bolus 0.4 mg either flumazenil placebo administer intravenously ( Minute 0 ) . At time 1H-MRS scan begin . Over next 6 minute , drip infusion flumazenil placebo mixed saline administer patient rate 0.1 mg flumazenil placebo per minute total 7 dos scan . A baseline pharmacokinetics ( PK ) sample drawn , process frozen intravenous line use draw sample remain patient sample draw . Seven additional PK sample ( 2-4 mL ) collect scan used evaluate level flumazenil circulate throughout bloodstream course infusion washout period . Following MRS fMRI , subject undergo 40-minute neuropsychologic battery . Other test procedure include liver function drug test . All procedure repeat one week later placebo flumazenil infusion ( base group he/she randomize ) . A follow-up phone call assess adverse event take place week 3 .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Flumazenil</mesh_term>
	<criteria>1 . Age : 18 old 2 . ICD9 diagnosis hepatic encephalopathy 3 . Ability feel comfortable confine area ( like MRI ) 4 . Ability provide inform consent 5 . Speaks fluent English without communication barrier 6 . Reliable family member friend able stay participant abstinence HE medication prior visit . 1 . Current DSMIVR diagnosis Alcohol Other Drug Abuse Dependence 2 . Positive screen alcohol abuse determine CAGE questionnaire 3 . Positive urine toxicity screen benzodiazepine medication illicit drug 4 . History longterm use benzodiazepine medication 5 . Current use nonbenzodiazepine agonist medication 6 . History Panic Disorder 7 . History Psychotic Disorder 8 . History seizure and/or Seizure Disorder 9 . History dysrhythmia , cardiovascular collapse , recent head trauma 10 . History side effect anticholinergic medication 11 . History cyclic antidepressant overdose poison 12 . Pregnant nursing 13 . Resides nurse home longterm care facility</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>hepatic encephalopathy</keyword>
	<keyword>flumazenil</keyword>
	<keyword>liver cirrhosis</keyword>
</DOC>